DURHAM, N.C., July 26, 2017 /PRNewswire/ -- Today, Accord Healthcare announced the acquisition of Ewing, New Jersey-based Essential Pharmaceuticals. Under the terms of the agreement, along with the Essential company, Accord has acquired the rights to sell Custodiol® HTK Solution (www.custodiol.com) in the United States and Canada. Custodiol® HTK Solution is a leading organ preservation solution indicated for perfusion and flushing of donor kidneys, liver, pancreas and heart prior to and after removal from donor.
"We are thrilled to be expanding on our capabilities of providing life-saving, affordable medicines and therapies to patients and healthcare providers alike. Custodiol® HTK is a vital product in the organ donation process and we are excited to include it in our product offering, as well as build upon the research and development programs in place for future organ preservation drug products," said Gerald Price, President of Accord Healthcare.
Commenting on the acquisition, Allan Weber, former CEO of Essential said: "As a growth oriented company, we couldn't have found a better partner than Accord Healthcare. Valued Custodiol® HTK customers can expect to see the same familiar faces of our Transplant Specialists, as well as experience the same outstanding customer service to which they have grown accustomed."
About Accord Healthcare
Accord Healthcare (www.accordhealthcare.us) is the 12th largest, and one of the fastest growing generic pharmaceutical in the United States, per IMS Health. The company's U.S. headquarters is in Durham, North Carolina, close to the Research Triangle Park. A young and dynamic pharmaceutical company, Accord is a part of the Intas Group headquartered in Ahmedabad India. Intas is a global pharmaceutical company (top line of USD 1.7 bn) engaged in the development, manufacturing and marketing of pharmaceutical finished formulations in over 75 countries. It has 14 manufacturing locations across the globe and employs over 14,000 people. Accord has FDA approval for 76 oral and injectable drug products in the U.S., and over 180 drug submissions either pending at FDA or in active development.
About Essential Pharmaceuticals
Essential Pharmaceuticals (www.essentialpharma.com) has served the transplant community with its products, service and contributions to transplant medicine since 2006. Custodiol® HTK was initially launched in 2000, but brought into the folds of Essential Pharmaceuticals when the company was founded by Allan Weber in 2006. Since 2006, Essential has grown into a significant, highly specialized business with a distinct sales, customer service and marketing team. Custodiol® HTK has grown to be one of the leading organ preservation solutions in the United States.